Equities research analysts expect that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will post earnings of ($1.53) per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Alnylam Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.47) and the lowest estimate coming in at ($1.58). Alnylam Pharmaceuticals reported earnings per share of ($1.07) in the same quarter last year, which would suggest a negative year over year growth rate of 43%. The business is scheduled to issue its next quarterly earnings results on Wednesday, August 8th.
According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full-year earnings of ($6.05) per share for the current fiscal year, with EPS estimates ranging from ($6.33) to ($5.64). For the next year, analysts anticipate that the business will post earnings of ($4.85) per share, with EPS estimates ranging from ($5.48) to ($3.70). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.47) by $0.06. Alnylam Pharmaceuticals had a negative net margin of 565.20% and a negative return on equity of 36.81%. The company had revenue of $21.90 million during the quarter, compared to the consensus estimate of $35.23 million. During the same period in the prior year, the firm earned ($1.25) earnings per share. Alnylam Pharmaceuticals’s revenue was up 15.3% on a year-over-year basis.
In other Alnylam Pharmaceuticals news, COO Yvonne Greenstreet sold 7,221 shares of the company’s stock in a transaction that occurred on Monday, March 26th. The shares were sold at an average price of $136.54, for a total transaction of $985,955.34. Following the transaction, the chief operating officer now owns 7,221 shares in the company, valued at approximately $985,955.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Laurie Keating sold 1,563 shares of the company’s stock in a transaction that occurred on Wednesday, June 20th. The shares were sold at an average price of $105.04, for a total transaction of $164,177.52. Following the transaction, the senior vice president now owns 16,063 shares in the company, valued at approximately $1,687,257.52. The disclosure for this sale can be found here. Insiders own 4.30% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Aperio Group LLC grew its holdings in Alnylam Pharmaceuticals by 24.7% in the 4th quarter. Aperio Group LLC now owns 21,078 shares of the biopharmaceutical company’s stock valued at $2,678,000 after buying an additional 4,170 shares during the last quarter. Teacher Retirement System of Texas grew its stake in Alnylam Pharmaceuticals by 256.4% in the fourth quarter. Teacher Retirement System of Texas now owns 24,050 shares of the biopharmaceutical company’s stock valued at $3,056,000 after acquiring an additional 17,302 shares during the period. California Public Employees Retirement System grew its stake in Alnylam Pharmaceuticals by 47.2% in the fourth quarter. California Public Employees Retirement System now owns 196,038 shares of the biopharmaceutical company’s stock valued at $24,907,000 after acquiring an additional 62,832 shares during the period. Daiwa Securities Group Inc. acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $343,000. Finally, KBC Group NV grew its stake in Alnylam Pharmaceuticals by 709.5% in the fourth quarter. KBC Group NV now owns 7,666 shares of the biopharmaceutical company’s stock valued at $974,000 after acquiring an additional 6,719 shares during the period. Institutional investors and hedge funds own 90.21% of the company’s stock.
Alnylam Pharmaceuticals traded up $1.51, reaching $104.20, during trading on Tuesday, Marketbeat Ratings reports. The company had a trading volume of 711,365 shares, compared to its average volume of 623,621. Alnylam Pharmaceuticals has a 52 week low of $70.76 and a 52 week high of $153.99. The company has a market cap of $10.32 billion, a P/E ratio of -19.23 and a beta of 2.67. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.61 and a quick ratio of 14.61.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.